Humanigen announces first patient dosed in NIH ACTIV-5/Big Effect trial evaluating lenzilumab for Covid-19
Lenzilumab is the Company’s lead product candidate and proprietary Humaneered anti-human granulocyte macrophage-colony stimulating factor (GM-CSF) monoclonal antibody designed to optimize antibody properties. ACTIV-5/BET, which is being conducted
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.